Tiziana Life Sciences Reports Allowance By FDA For At-Home Dosing Of Intranasal Foralumab For Multiple Sclerosis Treatment
Portfolio Pulse from Benzinga Newsdesk
The U.S. Food and Drug Administration (FDA) has approved at-home dosing of Intranasal Foralumab for multiple sclerosis patients. This decision was announced by Tiziana Life Sciences.
October 18, 2023 | 11:02 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tiziana Life Sciences has received FDA approval for at-home dosing of Intranasal Foralumab for multiple sclerosis patients. This could potentially increase the accessibility and usage of the drug.
The FDA approval for at-home dosing of Intranasal Foralumab is a significant milestone for Tiziana Life Sciences. This could potentially increase the accessibility and usage of the drug, leading to increased revenues for the company. Therefore, this news is likely to have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100